Skip to content

The Impact of Exercise on Subthalamic Nucleus Neural Activity in Parkinson's Disease

The Impact of Exercise on Subthalamic Nucleus Neural Activity in Parkinson's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05905302
Enrollment
15
Registered
2023-06-15
Start date
2023-08-15
Completion date
2024-09-20
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Brain Stimulation, Parkinson Disease

Brief summary

Fifteen PwPD who have undergone DBS surgery and utilize the Percept system will complete a FE and VE exercise session on a stationary cycle while Off antiparkinsonian medication. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre-, during FE or VE and post-exercise). The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III Motor Exam and upper extremity force-tracking task will be used to determine motor response to exercise.

Detailed description

Parkinson's disease (PD) is a progressive neurological disease, most prevalent in older adults, estimated to affect over 12 million people world-wide by 2040. While antiparkinsonian medication and deep brain simulation (DBS) are effective in managing disease symptoms, disease modification has remained elusive. Exercise has been proposed as the Universal Prescription for PD capable of slowing disease progression; stationary cycling in particular has been suggested as an ideal exercise modality for people with PD (PwPD).Our seminal tandem cycling study was the first to utilize forced exercise (FE) in human PD patients and demonstrate a 30% improvement in clinical ratings compared to voluntary exercise (VE). Briefly, FE is a mode of high intensity exercise originating in animal models of PD in which voluntary exercise rate is augmented, but not replaced. Thus, PwPD were assisted in pedaling at a higher rate (cadence) on the tandem cycle compared to those on a standard stationary cycle performing voluntary exercise (VE). This work resulted in a paradigm shift in terms of recommending high intensity exercise for PwPD. Currently, we are involved in two multi-site clinical trials aimed at identifying the potential of high intensity exercise to slow PD (2R01NS073717 & 1U01NS113851). Despite the potential of exercise to alter disease progression, its mechanism of action and effects on basal ganglia function are not understood. The loss of dopamine producing neurons associated with PD results in hypersynchrony of basal ganglia motor circuits that underlies PD symptoms. Recent animal studies using FE evaluated neural activity, local field potentials (LFPs), from the primary motor cortex (M1) to estimate the impact of exercise on basal ganglia function. Following FE, neural hypersynchrony in the beta (13-35Hz) frequency band was reduced in M1, which was proposed to underlie improved motor function. M1 activity is impacted by the activity in the subthalamic nucleus (STN), a structure in the basal ganglia, via the direct and indirect pathways. The impact of high intensity exercise, VE or FE, on STN hypersynchrony in humans is unknown. Recording of STN neural activity, until recently, was only possible during DBS surgery or in patients whose electrode was temporarily externalized immediately post-surgery. Neither approach is feasible or safe to systematically evaluate the effects of exercise on basal ganglia function. Recently, the Medtronic Percept DBS platform received FDA approval. The Percept platform records and streams neural activity from the DBS electrode within the STN. This project, for the first time, will record neural activity from the STN during two modes of high intensity exercise, FE and VE, in PwPD to identify the potential mechanism underlying the beneficial effects of exercise on PD. Our underlying hypothesis is that high intensity exercise reduces STN hypersynchrony which facilitates cortico-basal ganglia-thalamocortical circuit functionality thereby improving motor function following exercise.

Interventions

Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).

Sponsors

Jay Alberts
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Fifteen Parkinson's disease patients who have undergone DBS surgery and utilize the Percept system will complete a FE and VE exercise session on a stationary cycle while OFF antiparkinsonian medication. Bilateral neural activity of the STN will be continuously recorded.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult with a diagnosis of PD by a movement disorders neurologist 2. Previous placement, at least six months, of bilateral Medtronic Precept DBS as standard of care treatment for their PD. 3. Stable and clinically optimized DBS parameters for three months prior to enrollment. 4. Demonstrate the ability to safely mount and dismount a recumbent exercise cycle with an upright back. 5. Willingness to withhold antiparkinsonian medication and DBS stimulation. 6. Exercise clearance using the American College of Sports Medicine (ACSM) Pre-participation Health Screen: a. If the ACSM screen recommends medical clearance, the subject must obtain medical clearance by their health care provider prior to participation; b. Those who choose not to obtain physician clearance will not be eligible for participation.

Exclusion criteria

1. Diagnosis of dementia or any neurocognitive impairment that compromises the ability to provide informed consent. 2. A musculoskeletal issue that limits one's ability to cycle 3. Neurological disease other than Parkinson's disease (i.e. multiple sclerosis, stroke) that impacts motor or cognitive function 4. Uncontrolled cardiovascular risk factor such as a current cardiac arrhythmia, uncontrolled hypertension, untreated deep vein thrombosis, etc.

Design outcomes

Primary

MeasureTime frameDescription
Finger TappingPre- and Post-ExerciseFinger tapping portion of the the Movement Disorders Society-Unified Parkinson's Disease Rating Scale subscale III (MDS-UPDRS III). The MDS-UPDRS III assesses motor function in Parkinson's disease using eighteen items scored on a 0-4 scale resulting in a score ranging from 0-72. A higher score (larger number) indicates more motor symptoms. For this outcome, item number 4 (finger tapping rated 0-4) for the participant's dominant hand in the MDS-UPDRS III was analyzed.
Force TrackingPre- and Post-ExerciseParticipants were required to modulate the precision grip force of their dominant hand to match a target trajectory on a computer screen. Time within range is the percentage of the trial that participants were within 5% of the target force, with higher values indicating improved accuracy.
Local Field PotentialPre- and Post-ExerciseNormalized beta band activity (the change in beta power relative to a resting baseline) is reported as the mean across voluntary exercise (VE) and forced exercise (FE) sessions. The ON DBS condition was not tested for this outcome measure.

Countries

United States

Participant flow

Participants by arm

ArmCount
Experimental Arm
People with Parkinson's disease (PD) who have undergone DBS surgery and utilize the Percept system completed two stationary bike exercise sessions: forced exercise (FE) and voluntary exercise (VE). FE is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. VE is standard stationary cycling. The order in which the exercise sessions were completed was randomized. Participants completed the sessions OFF PD medication. The finger-tapping portion of the MDS-UPDRS III, force-tracking data, and local field potentials (LFPs) were collected before and after exercise sessions.
15
Total15

Baseline characteristics

CharacteristicExperimental Arm
Age, Continuous67.5 years
STANDARD_DEVIATION 4.8
Duration of Parkinson's disease9.2 years
STANDARD_DEVIATION 3.8
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
14 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
14 Participants
Region of Enrollment
United States
15 participants
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
9 Participants
Time since DBS placement1.5 years

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 150 / 150 / 150 / 15
other
Total, other adverse events
0 / 150 / 150 / 150 / 15
serious
Total, serious adverse events
0 / 150 / 150 / 150 / 15

Outcome results

Primary

Finger Tapping

Finger tapping portion of the the Movement Disorders Society-Unified Parkinson's Disease Rating Scale subscale III (MDS-UPDRS III). The MDS-UPDRS III assesses motor function in Parkinson's disease using eighteen items scored on a 0-4 scale resulting in a score ranging from 0-72. A higher score (larger number) indicates more motor symptoms. For this outcome, item number 4 (finger tapping rated 0-4) for the participant's dominant hand in the MDS-UPDRS III was analyzed.

Time frame: Pre- and Post-Exercise

ArmMeasureGroupValue (MEDIAN)
Experimental ArmFinger TappingON DBS3 score on a scale
Experimental ArmFinger TappingPre-FE OFF DBS3 score on a scale
Experimental ArmFinger TappingPost-FE OFF DBS3 score on a scale
Experimental ArmFinger TappingPre-VE OFF DBS3 score on a scale
Experimental ArmFinger TappingPost-VE OFF DBS3 score on a scale
Primary

Force Tracking

Participants were required to modulate the precision grip force of their dominant hand to match a target trajectory on a computer screen. Time within range is the percentage of the trial that participants were within 5% of the target force, with higher values indicating improved accuracy.

Time frame: Pre- and Post-Exercise

Population: Due to a technology error, data is unavailable for the first 2 participants. Complete data is available for 13 participants

ArmMeasureGroupValue (MEAN)Dispersion
Experimental ArmForce TrackingON DBS43.3 percentage of time within rangeStandard Deviation 23.5
Experimental ArmForce TrackingPre-FE OFF DBS44.9 percentage of time within rangeStandard Deviation 20.4
Experimental ArmForce TrackingPost-FE OFF DBS41.5 percentage of time within rangeStandard Deviation 21.4
Experimental ArmForce TrackingPre-VE OFF DBS43.0 percentage of time within rangeStandard Deviation 16.5
Experimental ArmForce TrackingPost-VE OFF DBS41.9 percentage of time within rangeStandard Deviation 16.3
Primary

Local Field Potential

Normalized beta band activity (the change in beta power relative to a resting baseline) is reported as the mean across voluntary exercise (VE) and forced exercise (FE) sessions. The ON DBS condition was not tested for this outcome measure.

Time frame: Pre- and Post-Exercise

Population: All 15 participants (30 exercise sessions, 1 FE and 1 VE per participant) were included in the analysis, but only 28 of the 30 total exercise sessions were included due to a technology error during 2 of the sessions.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental ArmLocal Field PotentialPre-FE OFF DBS Left STN100.0 percent power relative to baselineStandard Deviation 0
Experimental ArmLocal Field PotentialPre-FE OFF DBS Right STN100.0 percent power relative to baselineStandard Deviation 0
Experimental ArmLocal Field PotentialPost-FE OFF DBS Left STN131.0 percent power relative to baselineStandard Deviation 38.3
Experimental ArmLocal Field PotentialPost-FE OFF DBS Right STN120.5 percent power relative to baselineStandard Deviation 34
Experimental ArmLocal Field PotentialPre-VE OFF DBS Left STN100.0 percent power relative to baselineStandard Deviation 0
Experimental ArmLocal Field PotentialPre-VE OFF DBS Right STN100.0 percent power relative to baselineStandard Deviation 0
Experimental ArmLocal Field PotentialPost-VE OFF DBS Left STN118.8 percent power relative to baselineStandard Deviation 27.2
Experimental ArmLocal Field PotentialPost-VE OFF DBS Right STN110.8 percent power relative to baselineStandard Deviation 27.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026